BNGO

Bionano Genomics Inc

Add to Watchlist

Advanced Chart

3.430

+0.03(0.882%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.470

Open

3.430

VWAP

3.45

Vol

69.72K

Mkt Cap

11.54M

Low

3.400

Amount

240.32K

EV/EBITDA(TTM)

Total Shares

69.11M

-2.91M

EV/OCF(TTM)

P/S(TTM)

0.21

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

6.90M

-11.23%

7.83M

+28.98%

8.85M

+8.42%

Estimates Revision

The market is revising Downward the revenue expectations for Bionano Genomics, Inc. (BNGO) for FY2025, with the revenue forecasts being adjusted by -2.04% over the past three months. During the same period, the stock price has changed by -14.25%.

Revenue Estimates for FY2025

Revise Downward

-2.04%

In Past 3 Month

Stock Price

Go Down

-14.25%

In Past 3 Month

3 Analyst Rating

162.39% Upside

Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

162.39% Upside

Current: 3.430

Low

8.00

Averages

9.00

High

10.00

162.39% Upside

Current: 3.430

Low

8.00

Averages

9.00

High

10.00

Maxim

Jason McCarthy

Hold

Buy

upgrade

2025-05-20

Reason

Maxim

Jason McCarthy

Price Target

2025-05-20

upgrade

Hold

Buy

Reason

Maxim analyst Jason McCarthy upgraded Bionano Genomics to Buy from Hold with an $8 price target. The company has taken several steps to get itself back on track, including significant cost reductions, refocusing on its core optical genome mapping business, shifting focus from customer acquisition to expanding utilization, and securing cash runway into Q1 of FY26, the analyst tells investors in a research note. Optical genome mapping is also gaining traction at leading institutions, seeing real-world use, and generating publications, the firm adds.

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

$10

2025-04-09

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$10

2025-04-09

Initiates

Strong Buy

Reason

Scotiabank

Sung Ji Nam

Hold

Maintains

$1 → $4

2025-04-02

Reason

Scotiabank

Sung Ji Nam

Price Target

$1 → $4

2025-04-02

Maintains

Hold

Reason

Ladenburg Thalmann

Jeff Cohen

Strong Buy

Hold

Downgrades

n/a

2024-11-15

Reason

Ladenburg Thalmann

Jeff Cohen

Price Target

n/a

2024-11-15

Downgrades

Strong Buy

Hold

Reason

Ladenburg analyst Jeffrey Cohen downgraded Bionano Genomics to Neutral from Buy.

BTIG

Mark Massaro

Strong Buy

Hold

Downgrades

n/a

2024-09-10

Reason

BTIG

Mark Massaro

Price Target

n/a

2024-09-10

Downgrades

Strong Buy

Hold

Reason

Scotiabank

Sung Ji Nam

Buy

Hold

Downgrades

$6 → $1

2024-08-28

Reason

Scotiabank

Sung Ji Nam

Price Target

$6 → $1

2024-08-28

Downgrades

Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bionano Genomics Inc (BNGO.O) is -0.45, compared to its 5-year average forward P/E of -6.98. For a more detailed relative valuation and DCF analysis to assess Bionano Genomics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.98

Current PE

-0.45

Overvalued PE

3.29

Undervalued PE

-17.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.42

Current EV/EBITDA

-0.77

Overvalued EV/EBITDA

5.27

Undervalued EV/EBITDA

-18.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

23.60

Current PS

0.36

Overvalued PS

61.90

Undervalued PS

-14.69

Financials

Annual

Quarterly

FY2025Q1

YoY :

-26.37%

6.46M

Total Revenue

FY2025Q1

YoY :

-68.05%

-8.47M

Operating Profit

FY2025Q1

YoY :

-90.13%

-3.10M

Net Income after Tax

FY2025Q1

YoY :

-96.78%

-1.15

EPS - Diluted

FY2025Q1

YoY :

-90.18%

-2.76M

Free Cash Flow

FY2025Q1

YoY :

+41.30%

45.50

Gross Profit Margin - %

FY2025Q1

YoY :

-86.59%

-48.04

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BNGO News & Events

Events Timeline

2025-05-19 (ET)

2025-05-19

08:13:36

Bionano Genomics announces second Category I CPT code for OGM

2025-05-14 (ET)

2025-05-14

16:13:52

Bionano Genomics sees FY25 revenue $26M-$30M, consensus $30.33M

2025-05-14

16:12:15

Bionano Genomics reports Q1 revenue $6.46M, consensus $6.25M

News

3.5

06-18Newsfilter

Bionano Recaps Global Momentum Behind Optical Genome Mapping at the 2025 Annual Meeting of the European Society of Human Genetics Held Recently in Milan, Italy

9.0

05-19Newsfilter

Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

2.0

05-15SeekingAlpha

Biggest stock movers Thursday: CSCO, BNGO, and more